![declare timi 58 declare timi 58](https://elrincondesisifo.files.wordpress.com/2018/11/captura.jpg)
J.P.H.W., outside the submitted work, has grants, personal fees for lectures and consultancy fees (paid to his institution) from AstraZeneca and Novo Nordisk personal fees for lectures and consultancy fees (paid to his institution) from Boehringer Ingelheim, Janssen, Lilly, Mundipharma, Napp, Sanofi and Takeda and consultancy fees (paid to his institution) from Rhythm Pharmaceuticals and Wilmington Healthcare. report research grant support through Brigham and Womenʼs Hospital from Abbott, Amgen, Aralez, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., Daiichi-Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Roche, Takeda, The Medicines Company and Zora Biosciences. reports grants and personal fees from AstraZeneca, Bristol-Myers Squibb and Novo Nordisk, and personal fees from Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, Johnson & Johnson and Novartis.
![declare timi 58 declare timi 58](https://news-cdn.medlive.cn/uploadfile/ueditor/php/upload/image/20201118/1605664396629132.png)
discloses grants from AstraZeneca, Bristol-Myers Squibb, Sanofi Aventis and Amgen grants and personal fees from Arena, Daiichi Sankyo, Eisai, Eli Lilly and Janssen grants and consulting fees from Merck (additionally his spouse is employed by Merck) and personal fees from Aegerion, Allergan, AngelMed, Boehringer Ingelheim, Boston Clinical Research Institute, Icon Clinical, Lexicon, St Jude Medical, Xoma, Servier, AstraZeneca and Bristol-Myers Squibb.
![declare timi 58 declare timi 58](https://img.medscape.com/thumbnail_library/932578-thumb_800x450.jpg)
reports grants and personal fees from AstraZeneca and Novo Nordisk and personal fees from Abbott, Eli Lilly, Sanofi, Boehringer Ingelheim, Merck Sharp & Dohme, Medial Early-Sign and GlucoMe. The potential clinical benefit of combining sodium-glucose co-transporter-2 inhibitors with GLP-1 RAs, given some evidence of cardiovascular risk reduction with both classes, should be explored further.Ī.C. The effects of dapagliflozin on cardiorenal outcomes were generally consistent regardless of baseline GLA, with consistent benefits regardless of baseline metformin use. All of these outcomes were similar in those with versus those without baseline metformin use. The renal-specific outcome was reduced with dapagliflozin versus placebo in the overall cohort (HR 0.53), with no interaction by baseline GLA ( P interaction > .05). The overall HR for major adverse cardiovascular events (CVD, myocardial infarction or ischaemic stroke) was 0.93 (95% CI 0.84, 1.03) with dapagliflozin versus placebo, with no interaction by baseline GLA ( P interaction > .05). Dapagliflozin reduced the composite of cardiovascular death (CVD) and hospitalization for heart failure (HHF) versus placebo regardless of baseline GLA, with greater benefit in the small group of patients with baseline use of GLP-1 RAs (HR 0.37 vs. This post hoc analysis elaborates the efficacy and safety outcomes by baseline GLA for treatment effect and GLA-based treatment interaction. Materials and methodsĭECLARE-TIMI 58 assessed the cardiorenal outcomes of dapagliflozin versus placebo in patients with type 2 diabetes. To assess the associations between baseline glucose-lowering agents (GLAs) and cardiorenal outcomes with dapagliflozin versus placebo in the DECLARE-TIMI 58 study.